Home/Pipeline/CRN04894

CRN04894

Cushing’s Disease

Phase 2Active (CIRCUIT)

Key Facts

Indication
Cushing’s Disease
Phase
Phase 2
Status
Active (CIRCUIT)
Company

About Crinetics Pharmaceuticals

Crinetics Pharmaceuticals is building a premier endocrine-focused biopharma company by developing oral small-molecule drugs targeting G-protein coupled receptors (GPCRs). Its lead candidate, paltusotine, is in late-stage development for acromegaly and neuroendocrine tumors, positioning the company for near-term commercialization. The strategy leverages a proprietary platform and deep scientific expertise to address significant unmet needs in endocrinology, a field ripe for innovation.

View full company profile

About Crinetics Pharmaceuticals

Crinetics Pharmaceuticals is building a premier endocrine-focused biopharma company by developing oral small-molecule drugs targeting G-protein coupled receptors (GPCRs). Its lead candidate, paltusotine, is in late-stage development for acromegaly and neuroendocrine tumors, positioning the company for near-term commercialization. The strategy leverages a proprietary platform and deep scientific expertise to address significant unmet needs in endocrinology, a field ripe for innovation.

View full company profile

About Crinetics Pharmaceuticals

Crinetics Pharmaceuticals is building a premier endocrine-focused biopharma company by developing oral small-molecule drugs targeting G-protein coupled receptors (GPCRs). Its lead candidate, paltusotine, is in late-stage development for acromegaly and neuroendocrine tumors, positioning the company for near-term commercialization. The strategy leverages a proprietary platform and deep scientific expertise to address significant unmet needs in endocrinology, a field ripe for innovation.

View full company profile

About Crinetics Pharmaceuticals

Crinetics Pharmaceuticals is building a premier endocrine-focused biopharma company by developing oral small-molecule drugs targeting G-protein coupled receptors (GPCRs). Its lead candidate, paltusotine, is in late-stage development for acromegaly and neuroendocrine tumors, positioning the company for near-term commercialization. The strategy leverages a proprietary platform and deep scientific expertise to address significant unmet needs in endocrinology, a field ripe for innovation.

View full company profile